Phreesia (PHR) to Release Earnings on Wednesday

Phreesia (NYSE:PHR - Get Free Report) will likely be issuing its quarterly earnings data after the market closes on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $108.93 million for the quarter. Phreesia has set its FY 2026 guidance at EPS and its FY 2025 guidance at EPS.Persons that are interested in registering for the company's earnings conference call can do so using this link.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to analysts' expectations of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm's revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.58) earnings per share. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Trading Up 1.3 %

Shares of Phreesia stock traded up $0.33 during trading on Wednesday, reaching $25.79. 246,711 shares of the stock were exchanged, compared to its average volume of 389,288. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The stock's fifty day moving average is $27.53 and its 200 day moving average is $24.04. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -17.54 and a beta of 1.03.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PHR. Royal Bank of Canada raised shares of Phreesia from a "sector perform" rating to an "outperform" rating and raised their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Robert W. Baird reduced their target price on shares of Phreesia from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, December 11th. JMP Securities reiterated a "market outperform" rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Finally, Piper Sandler reissued an "overweight" rating and issued a $33.00 price objective (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. Thirteen research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $31.15.

Insiders Place Their Bets

In other Phreesia news, SVP David Linetsky sold 11,853 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $24.85, for a total value of $294,547.05. Following the sale, the senior vice president now directly owns 188,354 shares in the company, valued at $4,680,596.90. This represents a 5.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Allison C. Hoffman sold 3,495 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total value of $86,955.60. Following the sale, the general counsel now owns 116,296 shares in the company, valued at $2,893,444.48. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 195,740 shares of company stock worth $5,441,409. 5.80% of the stock is owned by corporate insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.